ArticleThe Lancet regional health. Europe2025
Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study.
Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02639936 (Performance of a New Generation IGRA in Immunocompromised Individuals), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Performance of a New Generation IGRA in Immunocompromised Individuals
Who cites it
11 citing papers in PubMed.
- Associations Between QuantiFERON-TB Gold Plus IFNγ Concentrations and Progression to Symptomatic Tuberculosis in Global High-Burden TB Settings.Open forum infectious diseases · 2026Article
- Interferon-gamma release assay screening before solid organ transplantation in a low-incidence country: a prospective single-center cohort study.Scientific reports · 2026Article
- Complementary effects of acid-fast staining, culture, and Xpert MTB/RIFBMC infectious diseases · 2026Article
- Dynamic, quantitative ESAT6-CFP10 skin test for tuberculosis risk prediction: a large-scale, multi-center, prospective cohort study.The Lancet regional health. Western Pacific · 2026Article
- Evaluation of a Fluorescence Immunoassay-Based IGRA for Latent Tuberculosis Diagnosis: A Simplified, Cost-Effective Alternative.Microorganisms · 2026Article
- Early Mycobacterial Antigens in the Immunodiagnosis of Latent Tuberculosis Infection.Pathogens (Basel, Switzerland) · 2026Review
- Lymphocyte-Predominant Ascites as a Clue to Peritoneal Tuberculosis: Two Case Reports and a Literature Review.Infection and drug resistance · 2026Article
- A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2026 Update for Clinicians and Scientists.Pathogens & immunity · 2026Review
- Unlocking Medical Breakthroughs: The Transformative Role of Case Reports in Clinical Discovery.Reports (MDPI) · 2025Article
- Commentary on: diagnostic accuracy and predictive value of the QuantiFERON-TB Gold Plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study.The Lancet regional health. Europe · 2025Article
- Biliary microbiota in disease-free, obstructive and post-drainage biliary tracts.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
44 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In low tuberculosis (TB)-endemic countries, tuberculosis preventive therapy (TPT) is recommended for immunocompromised individuals with a positive immunodiagnostic test. This study aimed to assess the performance of the QuantiFERON-TB Gold Plus (QFT+) assay and predictive power for future tuberculosis in immunocompromised individuals. Methods: In this prospective observational study, immunocompromised adults ≥18 years of age including people living with HIV (PLHIV), chronic renal failure, rheumatoid arthritis, solid-organ transplantation or stem-cell transplantation, and immunocompetent adults with and without TB-disease were recruited at 21 sites in 11 European countries and tested with the QFT+ assay. Individuals without TB-disease were followed up for the development of tuberculosis. TB incidence rates (IR) were calculated, stratified by QFT+ results and acceptance of TPT. This study is registered with Clinicaltrials.gov, NCT02639936. Findings: A total of 2663 individuals (1115 female, 1548 male) were enrolled from 03/11/2015 to 29/03/2019. Persons without tuberculosis were followed up for at least two years. Among 1758 immunocompromised individuals without active tuberculosis, 13.6% had positive QFT+ results. Sensitivity and specificity for TB-disease were 70.0% (52.1-83.3%) and 91.4% (89.6-92.9%), respectively, in immunocompromised, and 81.4% (76.6-85.3%) and 96.0% (92.5-97.9%), respectively, in immunocompetent individuals. During 2457 cumulative years of follow-up among 932 individuals with chronic renal failure, rheumatoid arthritis, solid-organ transplantation or stem-cell transplantation, including 83 persons with a positive QFT+ test without TPT, no-one developed active tuberculosis. In contrast, among 642 PLHIV without TPT, one with an indeterminate QFT+ and 3/30 individuals with a positive QFT+ developed active tuberculosis; all had detectable HIV-replication and low CD4 T-cell counts (incidence 4.1 (95% CI (1.3-12.4) per 100 person-years). No individuals receiving TPT developed active tuberculosis during 269 years of follow-up. Interpretation: In immunocompromised individuals in low TB-endemic countries, the 2-year-risk for active tuberculosis was highest among PLHIV with detectable HIV-replication and low CD4-counts. In this study, the QFT+ assay did not strongly predict progression to active tuberculosis, which emphasises the need to incorporate additional risk factors. Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.